Figure 7.
NST-628 enhances the efficacy of KRASG12C inhibition. A, Tumor volume of NCI-H23 tumors and (B) body weights of NCI-H23 tumor-bearing mice treated with 2 mg/kg NST-628, 100 mg/kg qd sotorasib, or a combination of NST-628 and sotorasib. C, Phospho-ERK levels in NCI-H23 endpoint tumors from A and B collected 4 hours after last dose.